El interés en corto de BioCardia da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de BioCardia. Los datos de interés en corto se actualizan cada dos semanas.

BioCardia (NASDAQ:BCDA) Bolsa, Informe de interés en corto

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

EsoBiotec SA, a biotechnology company specializing in in vivo cell therapies, has announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44350232/esobiotec-to-be-acquired-by-astrazeneca-to-advance-cell-therapy-ambition" rel="noreferrer noopener">definitive agreement to be acquired</a> by AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>).
The agreement represents a major step forward for EsoBiotec, which has demonstrated encouraging early clinical results with its Engineered NanoBody Lentiviral (ENaBL) platform.
AstraZeneca is acquiring all of EsoBiotec&#8217;s outstanding equity for a total of up to $1 billion. The deal includes an initial $425 million payment at closing, with up to an additional $575 million in contingent consideration based on development and regulatory milestones.
The transaction is expected to be finalized in the second quarter of 2025. EsoBiotec will continue operations in Belgium as a wholly owned subsidiary of AstraZeneca.
&#8220;We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy,&#8221; said AstraZeneca Executive Vice President, Oncology Haematology R&amp;D, Susan Galbraith.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44313315/perspective-therapeutics-cancer-focused-radiotherapy-portfolio-has-upside-potentional-says-analyst" rel="noreferrer noopener">Perspective Therapeutics&#8217; Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst</a>
EsoBiotec&#8217;s&nbsp;ENaBL platform utilizes highly targeted lentiviruses to deliver genetic instructions directly to immune cells like T cells. The technology programs these cells to recognize and destroy cancerous cells or autoreactive cells related to immune-mediated diseases.
In contrast to conventional treatments that require extracting cells from patients, modifying them externally, and enduring prolonged manufacturing periods, ENaBL works by enhancing the immune system within the patient&#8217;s body itself, by administering therapies through a simple intravenous (IV) injection.
AstraZeneca held $5.6 billion in <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/901832/000165495425001189/a1107w.htm" rel="noreferrer noopener">cash </a>and equivalents as of December 31.
Price Action: AZN shares traded lower by 0.66% at $77.08 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44276870/ionis-pharmaceuticals-partners-with-japan-based-ono-pharmaceutical-for-rare-blood-disease-drug-in-over-800-million-deal" target="_blank" rel="noreferrer noopener">Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal</a></li>
</ul>
Photo via Shutterstock.

Equities

News

General

AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details

A renowned industry analyst has said that Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://in.benzinga.com/top-stories/25/03/44313558/nvidia-stock-reached-all-time-highs-after-jensen-huangs-ces-keynote-will-next-weeks-gtc-spark-another-surge">GTC 2025 conference</a> could serve as a key turning point for its stock—but only if the company tackles investor concerns around its next-gen AI chips, server production, and the future of scaling laws.
What Happened: In a detailed research note released Sunday, noted analyst Ming-Chi Kuo outlined what investors should watch for at Nvidia's GTC 2025, calling it a potential "short-term catalyst" for the chipmaker's share price rebound—if expectations are met.
"Nvidia's AI server investment trends hinge on three critical issues: the continuing effectiveness of scaling laws, the production ramp-up of new AI servers, and geopolitical uncertainties," Kuo wrote.
The centerpiece of Nvidia's hardware announcements will likely be the B300 AI chip, expected to deliver a 50% performance boost over its predecessor, the B200.
See Also:&nbsp;<a href="https://www.benzinga.com/news/management/25/01/43274796/jensen-huang-loses-20b-in-wealth-how-deepseek-hit-nvidia-stock-and-worlds-richest-people" target="_blank" rel="noreferrer noopener">Jensen Huang Loses $20B In Wealth: How DeepSeek Hit Nvidia Stock And World's Richest People</a>
Kuo says the B300's expanded high-bandwidth memory—from 192GB to 288GB—will be a highlight. It will come in both dual-die (CoWoS-L) and single-die (CoWoS-S) variants, with trial production beginning in the second quarter of 2025 and mass production in the third quarter.
The analyst also noted that the GB300 NVL72 server—designed to replace the widely anticipated but delayed GB200 NVL72—will maintain the same rack dimensions and power needs, making it easier for data centers to upgrade without major overhauls.
"The market widely recognizes the production hurdles of GB200 NVL72," Kuo said. "If Nvidia could highlight real-world data center deployments of GB200 NVL72, underscore the upgrade advantages from B200 to B300, and clarify the B300 production timeline, it could sharpen market expectations for the B300 investment thesis."
He added that edge AI devices are another emerging growth vector, though they will likely take a backseat at GTC, with AI PC solutions such as N1X and N1 expected to debut later this year at Computex.
Despite the conference's strong focus on server infrastructure, Kuo said geopolitical tensions are unlikely to be addressed in any meaningful way.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia GTC 2025: Hardware Predictions and Investment Trend Analysis Click to read<a href="https://t.co/C05rJD5O8C">https://t.co/C05rJD5O8C</a> <a href="https://t.co/7SdS1WiUlx">pic.twitter.com/7SdS1WiUlx</a>
&mdash; 郭明錤 (Ming-Chi Kuo) (@mingchikuo) <a href="https://twitter.com/mingchikuo/status/1901266994214879331?ref_src=twsrc%5Etfw">March 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.Play
Why It's Important: The upcoming GTC 2025 conference is crucial for Nvidia as it follows a period of fluctuating stock performance. The company&#8217;s stock reached all-time highs after CEO Jensen Huang&#8217;s keynote at CES but has since seen a decline.
The GTC conference, often dubbed the Global AI Conference, is anticipated to be a pivotal moment for Nvidia, potentially sparking another surge in stock value.
In <a href="https://www.benzinga.com/news/24/03/37803088/nvidia-gtc-2024-ceo-huang-highlights-the-past-present-and-future-of-ai-a-new-industry-has-emerged">GTC 2024</a>, Huang underscored the transformative impact of AI, marking the emergence of a new industry.&nbsp;
Price Action: Nvidia&#8217;s stock rose 0.73% in pre-market trading on Monday to $122.56, following a 5.27% surge earlier on Friday, closing at $121.67. Year-to-date, the stock is down 12.03%, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42260222/how-nvidia-ceos-clever-but-nerdy-pick-up-line-turned-a-homework-proposal-into-marriage-while-building-338-trillion-ai-chip-giant-along-the-way" target="_blank" rel="noreferrer noopener">How Nvidia CEO Jensen Huang's Clever Pick-Up Line Turned A Homework Proposal Into Marriage While Building $3.38 Trillion AI Chip Giant Along The Way</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

NVDA

GTC 2025 Could Reignite Nvidia's Stock Rally, But Only If B300, AI Server Roadmap, And Scaling Concerns Are Addressed, Says Top Analyst

<a href="https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/" title="https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/">https://www.reuters.com/technology/intels-new-ceo-lip-bu-tan-has-history-successful-underdog-2025-03-13/</a>

Management

INTC

Reuters Reported New Intel CEO Lip-Bu Tan Plans To Overhaul Chip Design And Manufacturing Businesses; Plans To Restart AI Effort, Produce Chips At Annual Cadence; Plans To Examine Further Cuts To Reduce Bloa

Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Neutral and lowers the price target from $13 to $11.

Price Target

Analyst Ratings

RIVN

Mizuho Maintains Neutral on Rivian Automotive, Lowers Price Target to $11

Buybacks

BANC

Banc Of California Plans Repurchase Of Up To $150M Of Common Stock

Juniper Village at Paramus, a community with 98 assisted living units and 22 memory care units, has been operated by Juniper Communities, an operator of 28 senior housing communities across five states, since February 2021.&nbsp;

Health Care

National Health Investors Invested $46.3M To Acquire Juniper Village At Paramus, A Senior Housing Community In Bergen County, NJ

Contracts

KBR Bags $176M Advanced Space Technology Research And Optimization Contract For Air Force Research Laboratory

NAAS

NaaS Technology Announced A Strategic Partnership With Xiaomi Auto, A Subsidiary Of Xiaomi Group; Xiaomi Auto Users Will Be Able To Access NaaS's Charging Network, Through Xiaomi Auto App And The In-vehicle Charging Navigation System

Zapp EV can now deliver the i300 throughout the European Union.

ZAPP

Zapp Electric Vehicles Received The Required Certificate From The National Standards Authority Of Ireland Confirming European Community Whole Vehicle Type Approval For i300, The Company's Electric Urban Motorcycle

In addition, there are no changes to projected EBITDA ranges of $175 - $225 million of annual run rate EBITDA based on optimized G1 Dallas production, and the $650 - $750 million annual run-rate EBITDA estimate based on optimized production at G1 Dallas and G2 Austin.&nbsp;

Earnings

Guidance

T1 Energy Reaffirms $75M-$125M Full-year 2025 EBITDA Based On Projected 2025 Module Production Of 3.4 Gw At G1 Dallas

Townsquare Media Board Increases Quarterly Dividend To $0.20

T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) reported quarterly losses of $(0.22) per share. This is a 52.17 percent increase over losses of $(0.46) per share from the same period last year. The company reported $2.94 million in sales this quarter.

T1 Energy Q4 2024 GAAP EPS $(0.22) Up From $(0.46) YoY, Sales $2.94M

Townsquare Media Sees Q1 Revenue Of $98M - $100M Vs. $103.484M Est.

Proceeds from the sale will be used for general corporate purposes, with a focus towards reinvestment in the Company's oil and gas operations. Revenues from the divested business, which was represented as the Company's Contract Drilling segment, totaled approximately $3,162,000 for the trailing-twelve-months ended December 31, 2024.
Strategic Rationale
This transaction represents a further step in Barnwell's plan for streamlining its holding company operations, simplifying its corporate and accounting structure. This transaction will allow Barnwell's Board to proceed with its plans to meaningfully decrease general and administrative expenses and public company costs, including implementing such steps as transitioning personnel to Calgary or elsewhere, reducing the Company's legacy footprint in Hawaii.
The sale of Water Resources simplifies the equity story for Barnwell as investors will be able to focus on the significant opportunities the Company has identified in its oil and natural gas business. The combination of the proceeds from the sale of Water Resources and anticipated holding company savings also further improves Barnwell's financial position and balance sheet, which has no bank debt.

Asset Sales

Barnwell Industries Announced The Sale Of Its Wholly Owned Subsidiary, Water Resources International For $1.05M

Townsquare Media Sees FY25 Revenue Of $435M - $455M Vs. $450.648M Est.

Mizuho analyst Vijay Rakesh maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $515 to $430.

TSLA

Mizuho Maintains Outperform on Tesla, Lowers Price Target to $430

Key Findings
<ul>
<li>The publication describes CD388 and its potential for universal activity across influenza A and B viruses in cellular and animal models.
<ul>
<li>Administration of CD388 resulted in the following:
<ul>
<li>Potent, universal activity against all influenza A and B virus strains, including high pathogenicity strains like H5N1, also known as avian influenza or bird flu, and strains that are resistant to approved neuraminidase inhibitors</li>
<li>Low potential for resistance development</li>
<li>Efficacy at similar exposures in immune-competent and immune-compromised lethal challenge models in mice demonstrating that efficacy is driven predominantly by the intrinsic antiviral activity of CD388</li>
</ul>
</li>
</ul>
</li>
</ul>
CD388 is currently under clinical evaluation in the ~5000 patient Phase 2b NAVIGATE trial, evaluating CD388 for the single-dose prevention of seasonal influenza in healthy unvaccinated adult subjects.

Biotech

CDTX

Cidara Therapeutics Announced The Publication Of Preclinical Data Assessing CD388, The Company's Influenza Drug-fc Conjugate, In The Peer-reviewed Scientific Journal Nature Microbiology

Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) reported quarterly earnings of $0.60 per share which met the analyst consensus estimate. This is a 76.47 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $117.81 million which beat the analyst consensus estimate of $116.41 million by 1.21 percent. This is a 2.64 percent increase over sales of $114.79 million the same period last year.

Earnings Beats

Townsquare Media Q4 Adj $0.60, Inline, Sales $117.81M Beat $116.41M Estimate

Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study, which will provide evidence of the potential efficacy of Gemini in the Company's target indications.&nbsp;
&nbsp;
n this study, human PBMCs were primed with either Gemini or placebo followed by challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) in vitro. HMGB-1 is an endogenous damage associated molecular pattern (DAMP) that is generated during tissue injury (e.g. during surgery) which drives the inflammatory response. LPS is an exogenous pathogen associated molecular pattern (PAMP) that is generated from a bacterial infection and drives the inflammatory response associated with infection (e.g. fever).
After exposure of Gemini-primed PMBCs to either HMGB-1 or LPS, levels of multiple proinflammatory and anti-inflammatory cytokines including IL-1 beta, TNF-alpha, IL-6, IL-1 Receptor Antagonist, and IL-10 were measured. Priming with Gemini significantly decreased proinflammatory cytokines and significantly increased anti-inflammatory cytokines, relative to placebo.&nbsp;

REVB

Revelation Biosciences Says Gemini Priming Attenuates The Inflammatory Response In Human Peripheral Blood Mononuclear Cells Exposed To Clinically Relevant Promoter Molecules Of Inflammation

Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 28 percent decrease over losses of $(0.25) per share from the same period last year.

BLTE

Belite Bio Q4 2024 GAAP EPS $(0.32) Misses $(0.31) Estimate, As Of December 31, 2024, The Company Had $31.7M In Cash

Markets

Press Releases

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Comments

BioCardia

Interés en corto

BioCardia (NASDAQ:BCDA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL